<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574064</url>
  </required_header>
  <id_info>
    <org_study_id>UCPH-KS-3-18</org_study_id>
    <nct_id>NCT03574064</nct_id>
  </id_info>
  <brief_title>Effects of Gut Peptides on Bone Remodeling</brief_title>
  <acronym>KS-3</acronym>
  <official_title>Investigation of GLP-2 Mechanism of Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will investigate effects of gut hormones on bone remodeling.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-terminal telopeptide (CTX)</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>CTX is a marker of bone resorption. Measured in serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal propeptide of type 1 procollagen (P1NP)</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>P1NP is a marker of bone formation. Measured in serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTH</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Bone marker. Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Bone marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in serum within 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Total and intact GIP. Measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glukagon-like peptide-1 (GLP-1)</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glukagon-like peptide-2 (GLP-2)</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Intact GLP-2. Measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PP</measure>
    <time_frame>-10 minutes to 600 minutes</time_frame>
    <description>Measured in plasma.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>-10 minutes to 60 minutes</time_frame>
    <description>Measured before blood sampling.</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>-10 minutes to 60 minutes</time_frame>
    <description>Measured before blood sampling.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucagon-Like Peptide-2 (GLP-2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose-dependent Insulinotropic polypeptide (GIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-2+GIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-2+GIP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucagon-Like Peptide-2 (GLP-2)</intervention_name>
    <description>Glucagon-Like Peptide-2 (GLP-2) injection.</description>
    <arm_group_label>GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose-dependent insulinotropic polypeptide (GIP)</intervention_name>
    <description>Glucose-dependent insulinotropic polypeptide (GIP) injection.</description>
    <arm_group_label>GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-2+GIP</intervention_name>
    <description>GLP-2+GIP injection.</description>
    <arm_group_label>GLP-2+GIP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women Age above 50 years Postmenopausal Caucasian BMI 18.5 to 28.0 kg/m2.

        Exclusion Criteria:

        Smoking Medication believed to influence study outcome Weight change more than 3 kg whitin
        the last 3 months Overweight surgery Intestinal surgery Hgb&lt;7,0 mmol/L Decreased renal
        function
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Kirsa Skov-Jeppesen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

